Last reviewed · How we verify

Bludigo — Competitive Intelligence Brief

Bludigo (Indigo carmine) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: indigo carmine. Area: Nephrology.

marketed indigo carmine Nephrology Small molecule Live · refreshed every 30 min

Target snapshot

Bludigo (Indigo carmine) — Provepharm Sas. Bludigo works by being absorbed by the body and then excreted in the urine, where it stains the ureteral orifices, making them visible during medical procedures.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Bludigo TARGET Indigo carmine Provepharm Sas marketed indigo carmine 2022-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

Sponsor landscape (indigo carmine class)

  1. Provepharm Sas · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Bludigo — Competitive Intelligence Brief. https://druglandscape.com/ci/indigo-carmine. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: